PART I . Overview Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases. We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the gre...
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001193125-26-086645 | EDGAR | 99K words |
| 2025-03-04 | 2024-12-31 | 0000950170-25-031309 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018447 | EDGAR | — |
| 2023-03-13 | 2022-12-31 | 0000950170-23-007609 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0000950170-22-005157 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-268059 | EDGAR | 72K words |
| 2025-08-07 | 2025-06-30 | 0001193125-25-174948 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066363 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-122833 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093311 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056269 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061516 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041335 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021369 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024465 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016883 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009695 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-24 | 0001193125-26-120691 | EDGAR | 7K words |
| 2026-03-03 | 0001193125-26-086629 | EDGAR | — |
| 2026-01-08 | 0001193125-26-006991 | EDGAR | — |
| 2025-11-06 | 0001193125-25-268043 | EDGAR | — |
| 2025-09-10 | 0001193125-25-200159 | EDGAR | — |
| 2025-08-27 | 0001193125-25-189109 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104546 | EDGAR | — |
| 2025-06-05 | 0001193125-25-135860 | EDGAR | — |
| 2025-05-08 | 0000950170-25-066355 | EDGAR | — |
| 2025-03-04 | 0000950170-25-031303 | EDGAR | — |
77 total filings indexed. 50 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001658551 |
| Ticker | AMLX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.amylyx.com |
| Listed | 2022-01-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report